508 related articles for article (PubMed ID: 22049909)
21. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2011 Jun; 28(6):501-10. PubMed ID: 21603985
[TBL] [Abstract][Full Text] [Related]
22. Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops.
Inoue D; Mohamed YH; Uematsu M; Kitaoka T
Cutan Ocul Toxicol; 2020 Jun; 39(2):158-164. PubMed ID: 32295438
[No Abstract] [Full Text] [Related]
23. Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells.
Hedengran A; Freiberg J; May Hansen P; Boix-Lemonche G; Utheim TP; Dartt DA; Petrovski G; Heegaard S; Kolko M
J Optom; 2024; 17(1):100481. PubMed ID: 37788596
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay.
Liang H; Baudouin C; Faure MO; Lambert G; Brignole-Baudouin F
Mol Vis; 2009 Aug; 15():1690-9. PubMed ID: 19710954
[TBL] [Abstract][Full Text] [Related]
25. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study.
Yu F; Liu X; Zhong Y; Guo X; Li M; Mao Z; Xiao H; Yang S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3385-93. PubMed ID: 23620425
[TBL] [Abstract][Full Text] [Related]
26. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride.
McCarey B; Edelhauser H
J Ocul Pharmacol Ther; 2007 Oct; 23(5):445-51. PubMed ID: 17941807
[TBL] [Abstract][Full Text] [Related]
27. Fluoroquinolone eye drop-induced cytotoxicity: role of preservative in P2X7 cell death receptor activation and apoptosis.
Dutot M; Pouzaud F; Larosche I; Brignole-Baudouin F; Warnet JM; Rat P
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2812-9. PubMed ID: 16799018
[TBL] [Abstract][Full Text] [Related]
28. In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells.
Kim EJ; Kim YH; Kang SH; Lee KW; Park YJ
Korean J Ophthalmol; 2013 Dec; 27(6):446-53. PubMed ID: 24311931
[TBL] [Abstract][Full Text] [Related]
29. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines.
Ammar DA; Kahook MY
Br J Ophthalmol; 2011 Oct; 95(10):1466-9. PubMed ID: 21602479
[TBL] [Abstract][Full Text] [Related]
30. The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells.
Paimela T; Ryhänen T; Kauppinen A; Marttila L; Salminen A; Kaarniranta K
Mol Vis; 2012; 18():1189-96. PubMed ID: 22605930
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells.
Ayaki M; Yaguchi S; Iwasawa A; Koide R
Clin Exp Ophthalmol; 2008 Aug; 36(6):553-9. PubMed ID: 18954319
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Glaucoma Medications on Corneal Wound Healing.
Pinheiro R; Panfil C; Schrage N; Dutescu RM
J Glaucoma; 2016 Jan; 25(1):122-7. PubMed ID: 26164144
[TBL] [Abstract][Full Text] [Related]
33. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
34. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride.
Xiong C; Chen D; Liu J; Liu B; Li N; Zhou Y; Liang X; Ma P; Ye C; Ge J; Wang Z
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1850-6. PubMed ID: 18436819
[TBL] [Abstract][Full Text] [Related]
35. [Toxicity of preserved and unpreserved beta-blocker eyedrops in an in vitro model of human conjunctival cells].
de Saint Jean M; Debbasch C; Brignole F; Rat P; Warnet JM; Baudouin C
J Fr Ophtalmol; 2000 Feb; 23(2):111-21. PubMed ID: 10705112
[TBL] [Abstract][Full Text] [Related]
36. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.
Pellinen P; Lokkila J
Ophthalmic Res; 2009; 41(2):118-22. PubMed ID: 19147999
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system.
Yee RW; Norcom EG; Zhao XC
Adv Ther; 2006; 23(4):511-9. PubMed ID: 17050493
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes.
Lee HJ; Jun RM; Cho MS; Choi KR
Cutan Ocul Toxicol; 2015; 34(3):195-202. PubMed ID: 25265260
[TBL] [Abstract][Full Text] [Related]
39. Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells.
Yanochko GM; Khoh-Reiter S; Evans MG; Jessen BA
Toxicol In Vitro; 2010 Jun; 24(4):1324-31. PubMed ID: 20144907
[TBL] [Abstract][Full Text] [Related]
40. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops.
Kahook MY; Noecker R
Adv Ther; 2008 Aug; 25(8):743-51. PubMed ID: 18670744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
